How could the generic approval of semaglutide affect the Government of Canada?
Generic semaglutide approval could save public payers $89-billion in drug costs The approval of generic semaglutide by Health Canada could significantly reduce the financial burden on public and private payers. Without generic options, public and private payers would pay $183-billion on over 300 drugs when they lose legal protection. However, if cheaper off-patent drugs become promptly available, the cost could drop to $89-billion. Generic drug prices in Canada are set through an agreement with public health plans, and once a generic version is launched, it is priced at 75 per cent or 85 per cent of the brand-name list price, eventually falling to 25 per cent or 35 per cent once three or more versions are on the market.
- Effect
- Strong negative
- How direct
- Brind's reasoning
- When
- Within weeks
- The story
- No new developments lately
How it reaches Government of Canada
-
Sandoz applied to Health Canada for approval of generic semaglutide following the patent expiration of Ozempic. Sandoz also released an analysis estimating that over 300 drugs will lose legal protection in Canada over the next decade.
The full event1independent outlet -
Once Health Canada approves the generic, it can hit pharmacy shelves. Generic drug prices are set via an agreement with public health plans, which are managed by the Government of Canada. The availability of these cheaper options could reduce the cost burden on public payers from a potential $183-billion to $89-billion across the 300+ drugs losing protection.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
federal government of Canada
Everything about Government of Canada
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- The market protections for Ozempic expired on Jan. 4, 2026.theglobeandmail.com
- Without generic options, public and private payers would pay $183-billion on more than 300 drugs when they go off-patent.theglobeandmail.com
- If cheaper off-patent drugs were promptly available, the cost could be $89-billion.theglobeandmail.com
- When the first generic version of an off-patent drug is launched, it is priced at 75 per cent or 85 per cent of the brand-name list price.theglobeandmail.com
Why it matters
The potential savings of $89-billion represent a massive financial opportunity for the Government of Canada and its associated public health plans. This is part of a larger trend, as Sandoz estimates that more than 300 drugs will go off-patent in Canada over the next decade, creating a 'golden decade' for cost reduction if regulatory hurdles are overcome.
This situation highlights the critical role of regulatory speed. The industry has noted that the backlog of generic submissions has doubled in the past year, and Health Canada's target of assessing submissions within 180 days was only met 72 per cent of the time in the 2025-26 fiscal year. The speed of approval directly dictates when these savings can be realized by the public system.
What we don't know yet
- How quickly will Health Canada approve the generic semaglutide product?
- Will the Government of Canada adopt policies to encourage private insurers to switch patients to lower-cost generics?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- theglobeandmail.comThursday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.